



PRESS RELEASE JUNE 30<sup>th</sup>, 2011

## INCREASED NUMBER OF SHARES AND VOTES IN MOBERG DERMA

**The number of shares and the number of votes in Moberg Derma AB (publ) have changed as a result of a new issue of 2,550,524 shares in total, in connection with Moberg Derma's listing on NASDAQ OMX Stockholm.**

Today, the last trading day of the month, there are in total 9,079,020 shares and 9,079,020 votes in Moberg Derma.

Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am (CET) on June 30<sup>th</sup>, 2011.

**For further information, please contact:**

Peter Wolpert, President and CEO of Moberg Derma

Telephone: +46 8 522 307 00

Mobile: +46 735 71 35

E-mail: [peter.wolpert@mobergderma.se](mailto:peter.wolpert@mobergderma.se)

Magnus Persson, IR

Mobile: +46 73-355 26 01

E-mail: [magnus.persson@mobergderma.se](mailto:magnus.persson@mobergderma.se)

**About Moberg Derma**

Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company's products are based on proven compounds, which reduce time to market, development costs and risk. The portfolio covers approved and launched products to projects in the preclinical phase. The company began operations at the Karolinska Institute in Stockholm in 2006. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: [www.mobergderma.se](http://www.mobergderma.se)